1. Cross Talk between COVID-19 and Breast Cancer
   Hamendra Singh Parmar et al, 2021, Current Cancer Drug Targets CrossRef
2. Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
   Samson Mathews Samuel et al, 2022, Biomolecules CrossRef
3. Bioinformatic Searching for Optimal RNA Targets of Dimeric Compounds Informs Design of a MicroRNA-27a Inhibitor
   Raphael I. Benhamou et al, 2022, ACS Chemical Biology CrossRef
4. GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
   Fionnuala Crowley et al, 2024, Frontiers in Oncology CrossRef
5. MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations
   Jingcheng Zhang et al, 2019, Frontiers in Oncology CrossRef
6. Regulatory MicroRNAs in T2DM and Breast Cancer
   Ilhaam Ayaz Durrani et al, 2021, Processes CrossRef
7. Onkodiabetológia II.
   Róbert János Bánhegyi et al, 2022, Orvosi Hetilap CrossRef
8. Anti-Obesity Medications in Cancer Therapy: A Comprehensive Insight
   Rajveer Shekhawat et al, 2021, Current Cancer Drug Targets CrossRef
9. Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
   Young-Gyun Seo, 2021, Journal of Obesity & Metabolic Syndrome CrossRef
10. Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity
    Marina Caputo et al, 2021, Frontiers in Endocrinology CrossRef
11. Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect
    Rosaria Vincenza Giglio et al, 2020, Metabolites CrossRef
12. Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy
    Pamela Soberanis Pina et al, 2024, Biologics: Targets and Therapy CrossRef